ClinicalTrials.gg
CompletedNCT06738979Updated Sep 25, 2026

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

A Phase 3 interventional study of TQF3510 (Semaglutide Injection) and Wegovy® in Obesity, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 66 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Enrollment
20th of 143
408 · median 100
Started
2025
with 22 others
Phase 3
42 of 143
10 open now
Registered
88th of 143
by date

Among the 143 studies testing semaglutide in Obesity, this one is the 20th largest by enrollment, is one of 23 that started in 2025, is one of 42 in phase 3, and was the 88th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in obese subjects (BMI≥28 kg/m2).

Equivalence tests were performed for the percentage (%) of weight loss at 44w relative to baseline at the primary endpoint. A meta-analysis was performed based on multiple registration studies of the original drug Wegovy® (semaglutide), and the final equivalence threshold was determined (-4.16%, 4.16%). It was assumed that the sample size ratio of the experimental group and the control group was 1:1, the overall difference between the experimental group and the control group was 0, the standard deviation of the reference original drug was 11%, and the degree of assurance (1-β) was 85%. Double unilateral t test was adopted, and double unilateral α=0.025. The sample size was 326 cases by the Power Analysis \& Sample Size (PASS) 2019 Software. Considering the 20% shedding rate, 408 patients were enrolled in this study, 204 in each group.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years old, gender is not limited;
  • (BMI) ≥ 28 kg/m2;
  • Self-report at least one unsuccessful diet and weight loss history;
  • Patients must give to this study before the trial and sign the informed consent voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women or men or women of childbearing age who had a pregnancy plan during the study period (including a spouse), or who refused to take the measures specified in the programme during the study period;
  • Have a history of diabetes of any type;
  • Patients who had used any hypoglycemic drugs within 90 days before screening;
  • Personal or first-degree relatives have a personal or family history of thyroid C-cell tumor or multiple endocrine tumor syndrome type 2;
  • Use of any drugs for weight management within 90 days prior to screening;
  • Previous or planned weight loss related treatment through surgery or other weight loss means during the study period;
  • Have a history of major depression or serious mental illness;
  • Mental Health Scale (PHQ-9) score ≥ 15 during screening;
  • History of acute pancreatitis within 180 days prior to screening;
  • Have a history of chronic pancreatitis or pancreatic surgery;
  • Laboratory tests during screening meet any of the following criteria:

    1. (ALT)> 2.5× (ULN), aspartate aminotransferase (AST)>2.5 ULN;
    2. Estimated (eGFR) \< 30 mL/min/1.73m2;
    3. calcitonin ≥ 50 ng/L (pg/mL);
    4. Triglyceride (TG) ≥500 mg/dl (5.7mmol/L);
    5. Thyroid stimulating hormone (TSH) >6 mIU/L or \<0.4 mIU/L.
  • When virological tests at the time of screening show any of the following:

    1. virus (HCV) antibody positive, and HCV virus titer detection value exceeds the upper limit of normal value;
    2. positive and Hepatitis B virus (HBV) DNA test value exceeds the upper limit of normal value;
    3. positive;
    4. Active syphilis: the screening period of treponema pallidum antibody positive and non-Treponema pallidum serum test (RPR or TRUST) positive;
  • Uncontrolled or poorly treated hypertension;
  • cardiovascular and cerebrovascular disease in the 6 months prior to screening;
  • People who are allergic to Semaglutide injection or any component of Wegovy®, or to other GLP-1 receptor agonists, or who have a pre-existing allergic disorder;
  • Participated in any other clinical trial within 3 months prior to screening;
  • The subject is unable to comply with the treatment plan and diet and exercise plan established by the investigator;
  • There are secondary causes affecting body weight;
  • There is hypothyroidism at the time of screening that is not controlled with stable drug dosages;
  • Have a history of major surgery within 6 months prior to screening;
  • A history of drug abuse or alcohol dependence within the 6 months prior to screening;
  • History of malignant tumor within 5 years before screening;
  • Patients with other diseases that the researchers assessed would affect the safety of the subjects, affect the efficacy evaluation or compliance, or other conditions that the researchers considered unsuitable for enrollment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    TQF3510

    TQF3510: The drug treatment cycle was 44 weeks, including a dose escalation period of 16w and a stable dose period of 28w.

    Drug: TQF3510 (Semaglutide Injection)

  • Active comparator
    Wegovy®

    Wegovy® : The drug treatment cycle consisted of a dose escalation period of 16w and a stable dose period of 28w.

    Drug: Wegovy®

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage (%) of body weight loss

    Percentage (%) of body weight loss relative to baseline in both groups at week 44.

    Time frame: Baseline to week 44

Secondary outcomes

  1. Proportion of subjects with a body weight loss of ≥5%

    Proportion of subjects with a body weight loss of ≥5% from baseline at week 44.

    Time frame: Baseline to week 44

  2. Waist circumference change from baseline

    Waist circumference change from baseline at week 44.

    Time frame: Baseline to week 44

07

Study locations

66 sites
  • Hefei Third People's Hospital
    Hefei, Anhui 230000, China
  • Xuancheng People'S Hospital
    Xuancheng, Anhui 242000, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400010, China
  • The Southwest Hospital of Amu
    Chongqing, Chongqing Municipality 400038, China
  • Fuling Hospital affiliated to Chongqing University
    Chongqing, Chongqing Municipality 408107, China
  • Fujian Provincial Hospital
    Fuzhou, Fujian 350001, China
  • Mengchao Hepatobiliary Hospital Of Fujian Medical University
    Fuzhou, Fujian 350001, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350001, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730700, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730700, China
  • Nanxishan Hospital of Guangxi Zhuang Autonomous Region
    Guilin, Guangxi 541000, China
  • Liuzhou People'S Hospital
    Liuzhou, Guangxi 545000, China
  • The first Affiliated Hospital of GUANGXI medical university
    Nanning, Guangxi 530021, China
  • Wuzhou GongRen Hospital
    Wuzhou, Guangxi 543001, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563000, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061012, China
  • CangZhou Hospital of Integrated TCM-WM·HEBEI
    Cangzhou, Hebei 061012, China
  • The Affiliated Hospital of Chengde Medical College
    Chengde, Hebei 067000, China
  • Handan First Hospital
    Handan, Hebei 056000, China
  • Hebei Petro China Central Hospital
    Langfang, Hebei 065000, China
  • The Second Hospital Of Hebei Medical University
    Shijiazhuang, Hebei 050061, China
  • Tangshan GongRen Hospital
    Tangshan, Hebei 63000, China
  • Heilongjiang provincial hospital
    Haerbin, Heilongjiang 150036, China
  • The Third Affiliated Hospital of Qiqihar Medical College
    Qiqihar, Heilongjiang 161000, China
  • Anyang District Hospitai
    Anyang, Henan 455000, China
  • Luoyang Third People'S Hospital
    Luoyang, Henan 471002, China
  • The First affiliated Hospital of Nanyang Medical College
    Nanyang, Henan 473007, China
  • The Second Affiliated Hospital of Zhengzhou Univerisity
    Zhengzhou, Henan 450014, China
  • People'S Hospital of Zhengzhou
    Zhengzhou, Henan 451100, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 434000, China
  • Yichang Central People's Hospital
    Yichang, Hubei 443008, China
  • Yichang Central People's Hospital
    Yichang, Hubei 443100, China
  • The Fourth Hospital of Changsha
    Changsha, Hunan 410023, China
  • Loudi Central Hospital
    Loudi, Hunan 417000, China
  • The Second People Hospital of Lianyungang
    Lianyungang, Jiangsu 222000, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Jiangyin People' Hospital
    Wuxi, Jiangsu 214411, China
  • Jiangyin Hospital of Traditional Chinese Medicine
    Wuxi, Jiangsu 214499, China
  • XuZhou Cancer Hospital
    Xuzhou, Jiangsu 221018, China
  • XuZhou Central Hospital
    Xuzhou, Jiangsu 221018, China
  • First Affiliated Hospital Of Gannan Medical University
    Ganzhou, Jiangxi 341000, China
  • Xinyu People's Hospital
    Xinyu, Jiangxi 338000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
  • Genertec Liaoyou Gem Flower Hospiital
    Panjin, Liaoning 124000, China
  • The sixth people's hospital at of Shenyang
    Shenyang, Liaoning 110006, China
  • Shanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
  • Xi'An International Medical Center Hospital
    Xi'an, Shaanxi 710100, China
  • Binzhou medical college affiliated hospital
    Binzhou, Shandong 256603, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Affiliated Hospital of Jining Medical College
    Jining, Shandong 272001, China
  • Zibo Central Hospital
    Zibo, Shandong 255020, China
  • Shanghai Pudong New Area People's Hospital
    Shanghai, Shanghai Municipality 201299, China
  • Shanghai Jiading Central Hospital
    Shanghai, Shanghai Municipality 201800, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046000, China
  • FIRST HOSPITAL OF SHANXI Medical
    Taiyuan, Shanxi 30012, China
  • The Affiliated Hospital of Southwet Medical University
    Luzhou, Sichuan 646000, China
  • Suining Central Hospital
    Suining, Sichuan 629000, China
  • The Second People's Hospital of Yibin City
    Yibin, Sichuan 644000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • The First Affiliated Hospital of Shihezi University
    Shihezi, Xinjiang 832008, China
  • The Second Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
  • The First People's Hospital of Xiaoshan District
    Hangzhou, Zhejiang 311200, China
  • Huzhou Center Hostipal
    Huzhou, Zhejiang 313000, China
  • Jiaxing Second Hospital
    Jiaxing, Zhejiang 314000, China
  • Ruian People's Hospital
    Wenzhou, Zhejiang 325200, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Mar 2026, 11 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 11 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jul 2026 → Mar 2026 and completion Aug 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 18, 2024
StartActual
Mar 20, 2025
Primary completionActual
Mar 7, 2026was Jul 2026
CompletionActual
May 26, 2026was Aug 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Sep 25, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (6 China)
  • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • The Southwest Hospital of Amu · Chongqing, China
  • Fuling Hospital affiliated to Chongqing University · Chongqing, China
  • Shanghai Pudong New Area People's Hospital · Shanghai, China
  • Shanghai Jiading Central Hospital · Shanghai, China
  • Tianjin Medical University General Hospital · Tianjin, China
Show 6 removed
  • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • The Southwest Hospital of Amu · Chongqing, China
  • Fuling Hospital affiliated to Chongqing University · Chongqing, China
  • Shanghai Pudong New Area People's Hospital · Shanghai, China
  • Shanghai Jiading Central Hospital · Shanghai, China
  • Tianjin Medical University General Hospital · Tianjin, China
Sep 25, 2026
Primary completion
Jul 2026→Mar 7, 2026 (actual)
Sep 25, 2026
Study completion
Aug 2026→May 26, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Completed
    6 sites added, 6 sites removed
    Show 6 added (6 China)
    • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • The Southwest Hospital of Amu · Chongqing, China
    • Fuling Hospital affiliated to Chongqing University · Chongqing, China
    • Shanghai Pudong New Area People's Hospital · Shanghai, China
    • Shanghai Jiading Central Hospital · Shanghai, China
    • Tianjin Medical University General Hospital · Tianjin, China
    Show 6 removed
    • The First Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • The Southwest Hospital of Amu · Chongqing, China
    • Fuling Hospital affiliated to Chongqing University · Chongqing, China
    • Shanghai Pudong New Area People's Hospital · Shanghai, China
    • Shanghai Jiading Central Hospital · Shanghai, China
    • Tianjin Medical University General Hospital · Tianjin, China
    Primary completion Jul 2026→Mar 7, 2026 (now actual)
    Study completion Aug 2026→May 26, 2026 (now actual)
    + 2 other changes: index terms and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06738979
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Mar 20, 2025
Primary completion
Mar 7, 2026
Completion
May 26, 2026
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion